Report on a CAR T developer's 2026 interim results covering commercial progress, regulatory milestones, and clinical updates for multiple CAR T programs.
Key Takeaways
- Multiple allogeneic CAR T-cell products are under development based on the proprietary THANK‑u Plus ® platform
- In August 2026, both products successively received IND approvals from the NMPA
- Our revenue is recognized upon completion of ex-works delivery of products